Hydroxychloroquine inhibits proinflammatory signalling pathways by targeting endosomal NADPH oxidase

Annals of the Rheumatic Diseases

Volumn 76, Issue 5, 2017, Pages 891-897

  Müller Calleja, Nadine ^a   Manukyan, Davit ^a   Canisius, Antje ^a   Strand, Dennis ^a   Lackner, Karl J ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYCHLOROQUINE; INTERLEUKIN 1BETA; PHOSPHOLIPID ANTIBODY; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TUMOR NECROSIS FACTOR; ANTIRHEUMATIC AGENT; CYBB PROTEIN, HUMAN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G; MEMBRANE PROTEIN; REACTIVE OXYGEN METABOLITE; THROMBOPLASTIN;

ADULT; AGED; ANIMAL CELL; ARTICLE; CLINICAL ARTICLE; CONFOCAL LASER SCANNING MICROSCOPY; CONTROLLED STUDY; ENDOSOME; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIMIT OF QUANTITATION; MALE; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TARGETING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; VEIN THROMBOSIS; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CELL CULTURE; CHEMICALLY INDUCED; DIAGNOSTIC IMAGING; DISEASE MODEL; DRUG EFFECTS; ENZYME INDUCTION; ENZYMOLOGY; GENE EXPRESSION; GENETICS; INFERIOR CAVA VEIN; INTRAVITAL MICROSCOPY; METABOLISM; MIDDLE AGED; PROTEIN TRANSPORT; VENOUS THROMBOSIS; YOUNG ADULT;

ADULT; AGED; ANIMALS; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIRHEUMATIC AGENTS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; ENDOSOMES; ENZYME INDUCTION; FEMALE; GENE EXPRESSION; HUMANS; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN G; INTERLEUKIN-1BETA; INTRAVITAL MICROSCOPY; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MIDDLE AGED; MONOCYTES; NADPH OXIDASE; NF-KAPPA B; PROTEIN TRANSPORT; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; THROMBOPLASTIN; TUMOR NECROSIS FACTOR-ALPHA; VENA CAVA, INFERIOR; VENOUS THROMBOSIS; YOUNG ADULT;

EID: 85001819750     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2016-210012     Document Type: Article

References (56)

1. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, et al. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2010;69:20-8.
2. Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492-509.
3. Rainsford KD, Parke AL, Clifford-Rashotte M, et al. Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. Inflammopharmacology 2015;23:231-69.
4. Tang C, Godfrey T, Stawell R, et al. Hydroxychloroquine in lupus: emerging evidence supporting multiple beneficial effects. Intern Med J 2012;42:968-78.
5. Costedoat-Chalumeau N, Dunogué B, Morel N, et al. Hydroxychloroquine: a multifaceted treatment in lupus. Presse Med 2014;43(Pt 2):e167-180.
6. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. N Engl J Med 1991;324:150-4.
7. Katz SJ, Russell AS. Re-evaluation of antimalarials in treating rheumatic diseases: re-appreciation and insights into new mechanisms of action. Curr Opin Rheumatol 2011;23:278-81.
8. Kaiser R, Cleveland CM, Criswell LA. Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort. Ann Rheum Dis 2009;68:238-41.
9. Fangtham M, Petri M. 2013 update: Hopkins lupus cohort. Curr Rheumatol Rep 2013;15:360.
10. Belizna C. Hydroxychloroquine as an anti-thrombotic in antiphospholipid syndrome. Autoimmun Rev 2015;14:358-62.
11. Erkan D, Aguiar CL, Andrade D, et al. 14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends. Autoimmun Rev 2014;13:685-96.
12. Sperber K, Quraishi H, Kalb TH, et al. Selective regulation of cytokine secretion by hydroxychloroquine: inhibition of interleukin 1 alpha (IL-1-alpha) and IL-6 in human monocytes and T cells. J Rheumatol 1993;20:803-8.
13. van den Borne BE, Dijkmans BA, de Rooij HH, et al. Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma production by peripheral blood mononuclear cells. J Rheumatol 1997;24:55-60.
14. Tishler M, Yaron I, Shirazi I, et al. Hydroxychloroquine treatment for primary Sjögren's syndrome: its effect on salivary and serum inflammatory markers. Ann Rheum Dis 1999;58:253-6.
15. Achuthan S, Ahluwalia J, Shafiq N, et al. Hydroxychloroquine's efficacy as an antiplatelet agent study in healthy volunteers: a proof of concept study. J Cardiovasc Pharmacol Ther 2015;20:174-80.
16. Rand JH, Wu XX, Quinn AS, et al. Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug. Blood 2010;115:2292-9.
17. Kuznik A, Bencina M, Svajger U, et al. Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J Immunol 2011;186:4794-804.
18. Spencer NY, Engelhardt JF. The basic biology of redoxosomes in cytokine-mediated signal transduction and implications for disease-specific therapies. Biochemistry 2014;53:1551-64.
19. Li Q, Spencer NY, Oakley FD, et al. Endosomal Nox2 facilitates redox-dependent induction of NF-kappaB by TNF-alpha. Antioxid Redox Signal 2009;11:1249-63.
20. Oakley FD, Smith RL, Engelhardt JF. Lipid rafts and caveolin-1 coordinate interleukin-1beta (IL-1beta)-dependent activation of NFkappaB by controlling endocytosis of Nox2 and IL-1beta receptor 1 from the plasma membrane. J Biol Chem 2009;284:33255-64.
21. Tchikov V, Bertsch U, Fritsch J, et al. Subcellular compartmentalization of TNF receptor-1 and CD95 signaling pathways. Eur J Cell Biol 2011;90:467-75.
22. Prinz N, Clemens N, Strand D, et al. Antiphospholipid antibodies induce translocation of TLR7 and TLR8 to the endosome in human monocytes and plasmacytoid dendritic cells. Blood 2011;118:2322-32.
23. Prinz N, Clemens N, Canisius A, et al. Endosomal NADPH-oxidase is critical for induction of the tissue factor gene in monocytes and endothelial cells. Lessons from the antiphospholipid syndrome. Thromb Haemost 2013;109:525-31.
24. Müller-Calleja N, Köhler A, Siebald B, et al. Cofactor-independent antiphospholipid antibodies activate the NLRP3-inflammasome via endosomal NADPH-oxidase: implications for the antiphospholipid syndrome. Thromb Haemost 2015;113:1071-83.
25. Manukyan D, Müller-Calleja N, Jäckel S, et al. Cofactor-independent human antiphospholipid antibodies induce venous thrombosis in mice. J Thromb Haemost 2016;14:1011-20.
26. Kirou KA, Gkrouzman E. Anti-interferon alpha treatment in SLE. Clin Immunol 2013;148:303-12.
27. Aringer M, Smolen JS. Therapeutic blockade of TNF in patients with SLE-promising or crazy? Autoimmun Rev 2012;11:321-5.
28. Lackner KJ, von Landenberg C, Barlage S, et al. Analysis of prothrombotic effects of two human monoclonal IgG antiphospholipid antibodies of apparently similar specificity. Thromb Haemost 2000;83:583-8.
29. Prinz N, Häuser F, Lorenz M, et al. Structural and functional characterization of a human IgG monoclonal antiphospholipid antibody. Immunobiology 2011;216:145-51.
30. von Landenberg C, Lackner KJ, von Landenberg P, et al. Isolation and characterization of two human monoclonal anti-phospholipid IgG from patients with autoimmune disease. J Autoimmun 1999;13:215-23.
31. Döring Y, Hurst J, Lorenz M, et al. Human antiphospholipid antibodies induce TNFalpha in monocytes via Toll-like receptor 8. Immunobiology 2010;215:230-41.
32. Miller FJ Jr, Filali M, Huss GJ, et al. Cytokine activation of nuclear factor kappa B in vascular smooth muscle cells requires signaling endosomes containing Nox1 and ClC-3. Circ Res 2007;101:663-71.
33. Latz E, Schoenemeyer A, Visintin A, et al. TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat Immunol 2004;5:190-8.
34. von Brühl ML, Stark K, Steinhart A, et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med 2012;209:819-35.
35. Coward WR, Okayama Y, Sagara H, et al. NF-kappa B and TNF-alpha: a positive autocrine loop in human lung mast cells? J Immunol 2002;169:5287-93.
36. Guergnon J, Chaussepied M, Sopp P, et al. A tumour necrosis factor alpha autocrine loop contributes to proliferation and nuclear factor-kappaB activation of Theileria parva-transformed B cells. Cell Microbiol 2003;5:709-16.
37. Kim GY, Lee JW, Ryu HC, et al. Proinflammatory cytokine IL-1beta stimulates IL-8 synthesis in mast cells via a leukotriene B4 receptor 2-linked pathway, contributing to angiogenesis. J Immunol 2010;184:3946-54.
38. Salisbury JL, Condeelis JS, Satir P. Role of coated vesicles, microfilaments, and calmodulin in receptor-mediated endocytosis by cultured B lymphoblastoid cells. J Cell Biol 1980;87:132-41.
39. Wang LH, Rothberg KG, Anderson RG. Mis-assembly of clathrin lattices on endosomes reveals a regulatory switch for coated pit formation. J Cell Biol 1993;123:1107-17.
40. Nauseef WM. Assembly of the phagocyte NADPH oxidase. Histochem Cell Biol 2004;122:277-91.
41. IJdo JW, Mueller AC. Neutrophil NADPH oxidase is reduced at the anaplasma phagocytophilum phagosome. Infect Immun 2004;72:5392-401.
42. DeLeo FR, Burritt JB, Yu L, et al. Processing and maturation of flavocytochrome b558 include incorporation of heme as a prerequisite for heterodimer assembly. J Biol Chem 2000;275:13986-93.
43. Casbon AJ, Allen LA, Dunn KW, et al. Macrophage NADPH oxidase flavocytochrome B localizes to the plasma membrane and Rab11-positive recycling endosomes. J Immunol 2009;182:2325-39.
44. Dunmore BJ, Drake KM, Upton PD, et al. The lysosomal inhibitor, chloroquine, increases cell surface BMPR-II levels and restores BMP9 signalling in endothelial cells harbouring BMPR-II mutations. Hum Mol Genet 2013;22:3667-79.
45. Ohkuma S, Poole B. Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of pH by various agents. Proc Natl Acad Sci USA 1978;75:3327-31.
46. Solomon VR, Lee H. Chloroquine and its analogs: a new promise of an old drug for effective and safe cancer therapies. Eur J Pharmacol 2009;625:220-33.
47. Morgan D, Cherny VV, Murphy R, et al. The pH dependence of NADPH oxidase in human eosinophils. J Physiol 2005;569(Pt 2):419-31.
48. Mantegazza AR, Savina A, Vermeulen M, et al. NADPH oxidase controls phagosomal pH and antigen cross-presentation in human dendritic cells. Blood 2008;112:4712-22.
49. Chanock SJ, el Benna J, Smith RM, et al. The respiratory burst oxidase. J Biol Chem 1994;269:24519-22.
50. Quinn MT, Gauss KA. Structure and regulation of the neutrophil respiratory burst oxidase: comparison with nonphagocyte oxidases. J Leukoc Biol 2004;76:760-81.
51. El-Benna J, Dang PM, Gougerot-Pocidalo MA, et al. Phagocyte NADPH oxidase: a multicomponent enzyme essential for host defenses. Arch Immunol Ther Exp (Warsz) 2005;53:199-206.
52. Groemping Y, Rittinger K. Activation and assembly of the NADPH oxidase: a structural perspective. Biochem J 2005;386(Pt 3):401-16.
53. Vignais PV. The superoxide-generating NADPH oxidase: structural aspects and activation mechanism. Cell Mol Life Sci 2002;59:1428-59.
54. Giannakopoulos B, Krilis SA. The pathogenesis of the antiphospholipid syndrome. N Engl J Med 2013;368:1033-44.
55. Brandt KJ, Fickentscher C, Boehlen F, et al. NF-κB is activated from endosomal compartments in antiphospholipid antibodies-treated human monocytes. J Thromb Haemost 2014;12:779-91.
56. Pálfy M, Reményi A, Korcsmáros T. Endosomal crosstalk: meeting points for signaling pathways. Trends Cell Biol 2012;22:447-56.